Protea Announces Research Agreement with Mass General Hospital

        Protea Announces Research Agreement with Mass General Hospital

Developing molecular tests to help guide tumor immunotherapy

PR Newswire

MORGANTOWN, W. Va, Aug. 8, 2017

MORGANTOWN, W. Va, Aug. 8, 2017 /PRNewswire/ -- Protea Biosciences Group, Inc.
(OTCQB: PRGB) ("Protea") announced today that it had entered into a
Collaboration Research Agreement with the Vaccine and Immunotherapy Center
(VIC), Division of the Massachusetts General Hospital (MGH) and Harvard
Medical School. The goal is to co-develop a new diagnostic methodology that
will provide cancer cell molecular profiles, including the distribution of
drugs within cancer cells and molecular response indicators, to improve
patient treatment and outcomes.

(PRNewsfoto/Protea Biosciences Group, Inc.)

"This is a very exciting opportunity for our scientists at VIC to gain access
to an advanced molecular imaging technology and collaborate with Protea's
scientists to bring that technology to clinical relevance for our patients",
stated Mark Poznansky, M.D., Ph.D., Director of the MGH Vaccine and
Immunotherapy Center and the Principal Investigator for the joint research

"We are delighted to be undertaking the development of this groundbreaking
diagnostic technology with the VIC Team", commented Steve Turner, Protea
Chairman & CEO. He added, "Our collective goal is to improve the molecular
information rapidly available to patients and their physicians from tumor
samples, which can be used as the basis for decisions regarding both the
initiation and modification of specific immunotherapies for their treatment".

Immunotherapy is a type of cancer treatment that boosts the body's natural
defenses to fight the cancer. It uses substances made by the body or in a
laboratory to improve or restore the function of the body's natural immune
system. Immunotherapies can alter the immune environment of the tumor, leading
to better therapeutic outcome. The total Immunotherapy market is estimated to
be worth approximately $14 billion by 2019, rising to $34 billion by 2024, as
the treatment of cancer patients undergoes drastic changes over the next

Immunotherapies are increasingly being integrated into treatments for solid
tumors - drugs that have great promise for some patients but are expensive and
come with some significant adverse events. However currently, standard
clinical measurements only provide serum levels of drug and provide little or
no information on changes within the tumor. Patients currently undergo costly
therapy with significant potential side effects but without a robust means to
evaluate the impact of the therapy in the tumor microenvironment. For new
immunotherapies to have maximum impact in a cost-effective way, it will be
essential to generate more molecular information from tumor samples that can
support medical decision making at the start of, and throughout the process
of, treatment of the cancer. Developing the technology to provide this
molecular information is the goal of this joint research collaboration.

About Protea Biosciences Group, Inc.:  Protea Biosciences Group, Inc.
(OTCQB:PRGB) is a molecular information company providing innovative
bioanalytical solutions to the pharmaceutical and life science industries. The
Company has developed next gen technology that enables the rapid and direct
identification, mapping and display of the molecules present in all living
cells and tissue samples. Protea applies its technology to the development of
new molecular tests for the differential diagnosis of cancer, and the
comprehensive molecular profiling of human disease.

"Molecular information" refers to the generation and bioinformatic processing
of very large data sets, obtained by applying the Company's technology to
identify and characterize the proteins, metabolites, lipids and other
biologically-active molecules which are the byproducts of all living cells and
life forms. The company provides proprietary molecular information services to
its clients in the pharmaceutical and life science industries.

Forward-Looking Statements; This press release may contain statements relating
to future results or events, which are forward-looking statements.  Words such
as "expects", "intends", "plans", "may", "could", "should", "anticipates",
"likely", "believes" and words of similar import may identify forward-looking
statements. These statements are not historical facts, but instead represent
only the Company's belief regarding future events, many of which, by their
nature, are inherently uncertain and outside of the Company's control.  It is
possible that the Company's actual results and financial condition may differ,
possibly materially, from the anticipated results and financial condition
indicated in these forward-looking statements.  Further, information
concerning the Company and its business, including factors that potentially
could materially affect the Company's business and financial and other
results, are contained in the Company's filings with the Securities and
Exchange Commission, available at  All forward-looking statements
included in this press release are made only as of the date of this press
release, and we do not undertake any obligation to publicly update or correct
any forward-looking statements to reflect events or circumstances that
subsequently occur or of which we hereafter become aware.


Protea is a registered trademark of Protea Biosciences Group, Inc

View original content with

SOURCE Protea Biosciences Group, Inc.

Contact: For more Information: Protea Biosciences Group, Inc., 1311 Pineview
Dr., Morgantown, WV 26505 USA, Phone: 304.292.2226,,
Press spacebar to pause and continue. Press esc to stop.